South China Morning Post

AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would.

بقلم South China Morning Post

1 دقيقة قراءة
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

هل لديك أخبار لمشاركتها مع صناعة الفعاليات؟

أرسل بياناً صحفياً أو تلميحاً بقصة وتواصل مع آلاف المهنيين في مجال الفعاليات.

تواصل معنا→

المزيد في Startups & Entrepreneurship

رؤى ذات صلة